Results 31 to 40 of about 22,744 (213)

Overcoming steroid resistance in T cell acute lymphoblastic leukemia [PDF]

open access: yes, 2016
In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic ...
Goossens, Steven   +1 more
core   +3 more sources

Risk predictors of early recurrence in women with epithelial ovarian cancer in Lagos, Nigeria

open access: yesThe Pan African Medical Journal, 2020
INTRODUCTION: Epithelial ovarian cancer (EOC) is the most lethal gynaecological cancer with a recurrence rate as high as 85% after an initial treatment. However, there are currently no reliable means of predicting the risk of recurrence after first-line ...
Kehinde Sharafadeen Okunade   +4 more
doaj   +1 more source

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

open access: yes, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena   +4 more
core   +1 more source

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

open access: yes, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B.   +5 more
core   +2 more sources

Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma [PDF]

open access: yes, 2008
Objectives: Suboptimal debulking (>1 cm residual tumor) results in poor survival rates for patients with an advanced stage of ovarian cancer. The purpose of this study was to develop a prediction model, based on simple preoperative parameters, for ...
A. Baalbergen   +51 more
core   +7 more sources

3D laparoscopy as a tertiary cytoreductive (TCR) surgery in infiltrating ureter recurrent epithelial ovarian cancer – case report and a mini-review of the literature

open access: yesMenopause Review, 2018
The paper describes a case of a 61-year-old woman with recurrent epithelial ovarian cancer infiltrating the ureter treated with 3D laparoscopy as a tertiary cytoreductive surgery (TCR).
Tomasz Szopiński   +4 more
doaj   +1 more source

Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer

open access: yesFrontiers in Oncology, 2020
Purpose: To assess the survival outcomes of patients with metastatic prostate cancer (mPCa) who undergo greater cytoreductive radiotherapy in a real-world clinical practice and determine their prognostic factors.Methods: We performed a retrospective ...
Zitong Zhang   +12 more
doaj   +1 more source

Does the Performance of Splenectomy as Part of Cytoreductive Surgery Carry a Worse Prognosis Than in Patients Not Receiving Splenectomy? A Propensity Score Analysis and Review of the Literature

open access: yesJournal of Investigative Surgery, 2022
Background & Objectives Ultra-radical (UR) procedures, including splenectomy, are utilized to increase complete cytoreduction rates during Cytoreductive Surgery (CRS) performed with the aim of complete macroscopic clearance of disease.
James Davies   +4 more
doaj   +1 more source

Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. [PDF]

open access: yes, 2017
BackgroundProdrug-activator gene therapy with Toca 511, a tumor-selective retroviral replicating vector (RRV) encoding yeast cytosine deaminase, is being evaluated in recurrent high-grade glioma patients.
Gruber, Harry E   +14 more
core   +1 more source

Role for targeted resection in the multidisciplinary treatment of metastatic gastrointestinal stromal tumor [PDF]

open access: yes, 2019
The management of advanced gastrointestinal stromal tumors (GISTs) has evolved in the modern era due to the discovery of c-kit mutations and the development of tyrosine kinase inhibitors (TKIs).
Feizpour, Cyrus   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy